| Literature DB >> 23675129 |
M I Walash1, F Belal, N El-Enany, A A Abdelal.
Abstract
A simple and sensitive kinetic spectrofluorometric method was developed for the determination of some calcium channel blockers namely, verapamil hydrochloride, diltiazem hydrochloride, nicardipine hydrochloride and flunarizine. The method is based upon oxidation of the studied drugs with cerium (IV) ammonium sulphate in acidic medium. The fluorescence of the produced Ce (III) was measured at 365 nm after excitation at 255 nm. The different experimental parameters affecting the development and stability of the reaction product were carefully studied and optimized. The fluorescence-concentration plots were rectilinear for all the studied compounds over the concentration range of 0.01 to 0.12 μg mL(-1). The limits of detections for the studied compounds ranged from 2.93 × 10(-3) to 0.012 μg mL(-1) and limits of quantification from 9.76 × 10(-3) to 0.04 μg mL(-1) were obtained. The method was successfully applied to the analysis of commercial tablets. The results obtained were in good agreement with those obtained with reference methods.Entities:
Keywords: Cerium (IV); diltiazem hydrochloride; nicardipine hydrochloride; verapamil hydrochloride
Year: 2009 PMID: 23675129 PMCID: PMC3614771
Source DB: PubMed Journal: Int J Biomed Sci ISSN: 1550-9702
Figure 1Structural formulae of the studied drugs.
Performance data of the proposed method
| Parameter | Verapamil HCl | Diltiazem HCl | Nicardipine HCl | Flunarizine |
|---|---|---|---|---|
| Concentration range (μg mL-1) | 0.02-0.12 | 0.01-0.06 | 0.02-0.12 | 0.04-0.12 |
| Volume of 5 × 10-4 M Ce (IV), mL | 0.5 | 1 | 1.5 | 0.8 |
| Concentration of H2SO4 (M) | 1.25 | 1 | 1.5 | 1.5 |
| Time of heating (min) | 25 | 20 | 15 | 25 |
| Limit of detection (LOD) (μg mL-1) | 6.33 × 10-3 | 3.1 × 10-3 | 2.93 × 10-3 | 0.012 |
| Limit of quantification (LOQ) (μg mL-1) | 0.02 | 0.01 | 9.76 × 10-3 | 0.04 |
| Correlation coefficient (r) | 0.9998 | 0.9998 | 0.9999 | 0.9998 |
| Slope | 4260.00 | 7380.233 | 2992.857 | 3340.00 |
| Intercept | 7.133 | 9.512 | 3.670 | 4.60 |
| Sy/x | 3.110 | 3.210 | 0.344 | 2.530 |
| Sa | 26.750 | 32.100 | 2.924 | 26.820 |
| Sb | 37.020 | 32.380 | 4.095 | 40.000 |
| RSD (%) | 1.252 | 1.220 | 0.260 | 1.020 |
| % Error | 0.511 | 0.550 | 0.106 | 0.460 |
| Student’s | 1.19 | 0.28 | 1.47 | 0.11 |
| F test | 3.24 | 1.14 | 2.96 | 1.48 |
Sy/x, Standard deviation of the residuals; Sa, Standard deviation of the intercept; Sb, Standard deviation of the slope; % Error, %RSD/√n; RSD% = Relative standard deviation.
Figure 2Excitation and emission spectra of induced Ce(III) by oxidation of 0.06 μg mL-1 DLT with Ce (IV) where: (A), Excitation spectrum; (A`), Emission spectrum.
Figure 3Effect of volume of 5 × 10-4 M Ce (IV) on the relative fluorescence intensity. ●, 0.06 μg mL-1 DLT; □, 0.1 μg mL-1 VP; Δ, 0.1 μg mL-1 FZ; ■, 0.1 μg mL-1 NC.
Figure 4Effect of molar concentration of H2SO4 on the relative fluorescence intensity. ●, 0.06 μg mL-1 DLT; □, 0.1 μg mL-1 VP; Δ, 0.1 μg mL-1 FZ; ■, 0.1 μg mL-1 NC.
Figure 5Effect of the heating time on the relative fluorescence intensity. Δ, 0.06 μg mL-1 DLT; ●, 0.1 μg mL-1 VP; □, 0.1 μg mL-1 FZ; ■, 0.1 μg mL-1 NC.
Logarithm of the rate for different concentrations of the studied drugs by the proposed method
| Compound | Log ΔF/Δt | Log [drug] | Regression equation | Correlation coefficient | Rate constant (S-1) | Order of reaction (n) |
|---|---|---|---|---|---|---|
| Verapamil HCl | -1.22 | -7.39 | Log rate=5.950+0.970 log C | 0.9999 | 891251 | 0.970 |
| -0.92 | -7.09 | |||||
| -0.76 | -6.91 | |||||
| -0.63 | -6.79 | |||||
| -0.54 | -6.69 | |||||
| -0.46 | -6.61 | |||||
| Diltiazem HCl | -1.16 | -7.65 | Log rate=6.104+0.950 log C | 0.9998 | 1270574 | 0.950 |
| -0.89 | -7.35 | |||||
| -0.59 | -7.05 | |||||
| -0.50 | -6.96 | |||||
| -0.43 | -6.88 | |||||
| Nicardipine HCl | -1.15 | -7.42 | Log rate= 6.037+0.970 log C | 0.9999 | 1088930 | 0.970 |
| -0.86 | -7.11 | |||||
| -0.69 | -6.93 | |||||
| -0.57 | -6.81 | |||||
| -0.47 | -6.71 | |||||
| -0.39 | -6.63 | |||||
| Flunarizine | -1.04 | -7.00 | Log rate=5.834+0.981 log C | 0.9998 | 682339 | 0.981 |
| -0.86 | -6.83 | |||||
| -0.74 | -6.70 | |||||
| -0.65 | -6.61 | |||||
| -0.57 | -6.53 | |||||
Figure 6Plot of Log reaction rate (Log ΔF/Δt) versus Log concentration of: A, VP; B, DLT; C, NC; D, FZ.
Application of the rate constant method in the quantification of the studied drugs by the proposed method
| Compound | k`(S-1) | [drug] |
|---|---|---|
| Verapamil HCl | -4.190 × 10-4 | 0.41 × 10-8 |
| -4.100 × 10-4 | 0.81 × 10-8 | |
| -4.080 × 10-4 | 1.22 × 10-7 | |
| -4.053 × 10-4 | 1.63 × 10-7 | |
| -4.023 × 10-4 | 2.04 × 10-7 | |
| -4.000 × 10-4 | 2.44 × 10-7 | |
| Diltiazem HCl | -1.283 × 10-3 | 0.22 × 10-8 |
| -1.262 × 10-3 | 0.44 × 10-8 | |
| -1.235 × 10-3 | 0.89 × 10-8 | |
| -1.215 × 10-3 | 1.11× 10-7 | |
| -1.184 × 10-3 | 1.33 × 10-7 | |
| Nicardipine HCl | -1.263 × 10-3 | 0.39 × 10-8 |
| -1.225 × 10-3 | 0.78 × 10-8 | |
| -1.200 × 10-3 | 1.16 × 10-7 | |
| -1.176 × 10-3 | 1.55 × 10-7 | |
| -1.139× 10-3 | 1.94 × 10-7 | |
| -1.124 × 10-3 | 2.33 × 10-7 | |
| Flunarizine | -6.351 × 10-4 | 0.99× 10-8 |
| -6.296 × 10-4 | 1.48 × 10-7 | |
| -6.218 × 10-4 | 1.98 × 10-7 | |
| -6.162 × 10-4 | 2.47 × 10-7 | |
| -6.070 × 10-4 | 2.97 × 10-7 | |
Where k` is the pseudo first order rate constant.
Application of the fixed fluorescence method in the quantification of the studied drugs by the proposed method
| Compound | Time (sec.) | 1/t (sec.-1) | [drug] |
|---|---|---|---|
| Verapamil HCl | 1200 | 8.33 × 10-4 | 1.50 × 10-7 |
| 900 | 1.11 × 10-3 | 1.71 × 10-7 | |
| 600 | 1.67 × 10-3 | 2.04 × 10-7 | |
| Diltiazem HCl | 1200 | 8.33 × 10-4 | 4.43 × 10-8 |
| 600 | 1.67 × 10-3 | 8.09 × 10-8 | |
| 300 | 3.33 × 10-3 | 1.36 × 10-7 | |
| Nicardipine HCl | 900 | 1.11 × 10-4 | 8.91 × 10-8 |
| 600 | 3.30 × 10-3 | 1.16 × 10-7 | |
| 300 | 6.80 × 10-3 | 1.94 × 10-7 | |
| Flunarizine | 1200 | 8.33 × 10-3 | 1.48 × 10-7 |
| 600 | 1.67 × 10-3 | 1.90 × 10-7 | |
| 300 | 3.33 × 10-3 | 2.97 × 10-7 | |
Application of the fixed time method in the quantification of the studied drugs by the proposed method
| Compound | Time (min.) | Regression Equations | Correlation Coefficient |
|---|---|---|---|
| Verapamil HCl | 5 | F = 5.667 + 2621.429 C | r=0.9991 |
| 10 | F = 3.267 + 3048.571 C | r=0.9991 | |
| 15 | F = 5.467 + 3574.286 C | r=0.9992 | |
| 20 | F = 14.200 + 3811.429C | r=0.9993 | |
| 25 | F = 7.133 + 4260.000 C | r=0.9998 | |
| Diltiazem HCl | 5 | F = -2.814 + 2533.721 C | r=0.9991 |
| 10 | F = 12.116 + 3952.326 C | r=0.9995 | |
| 15 | F = 4.535 + 5290.698 C | r=0.9996 | |
| 20 | F = 9.512 + 7380.233 C | r=0.9998 | |
| Nicardipine HCl | 5 | F = -2.80 + 1554.286 C | r=0.9997 |
| 10 | F = 7.80 + 2188.571 C | r=0.9998 | |
| 15 | F = 3.67 + 2992.857 C | r=0.9999 | |
| Flunarizine | 5 | F = -1.00 + 1510.00 C | r=0.9993 |
| 10 | F = -1.20 + 2395.00 C | r=0.9993 | |
| 15 | F = -4.40 + 2750.00 C | r=0.9994 | |
| 20 | F = 6.40 + 2865.00 C | r=0.9996 | |
| 25 | F = 4.60 + 3340.00 C | r=0.9998 | |
Precision and accuracy of the proposed method for spectrofluorometric determination of pure VP
| Regimen | Parameters | Concentration Added (μg/mL) | Concentration Found (μg/mL) | Recovery % |
|---|---|---|---|---|
| Intra-day | 0.040 | 0.0392 | 98.00 | |
| 0.0395 | 98.75 | |||
| 0.0398 | 99.50 | |||
| ( | 98.75 | |||
| ± S.D. | 0.75 | |||
| 0.060 | 0.0598 | 99.67 | ||
| 0.0603 | 100.50 | |||
| 0.0607 | 101.17 | |||
| ( | 100.45 | |||
| ± S.D. | 0.75 | |||
| 0.080 | 0.0799 | 99.88 | ||
| 0.0789 | 98.63 | |||
| 0.0805 | 100.63 | |||
| ( | 99.71 | |||
| ± S.D. | 1.01 | |||
| Inter-day | 1st day | 0.080 | 0.0788 | 98.50 |
| 2nd day | 0.0815 | 101.88 | ||
| 3rd day | 0.0808 | 101.00 | ||
| ( | 100.46 | |||
| ± S.D. | 1.75 | |||
Each result is the average of three separate determinations.
Application of the proposed method to the determination of the studied drugs in dosage forms
| Compound | Proposed method | Comparison methods ( | ||
|---|---|---|---|---|
| Concentration taken (μg mL-1) | Concentration found (μg mL-1) | Recovery % | Recovery % | |
| Isoptin 80 mg tablets | 0.06 | 0.0606 | 101.00 | 98.58 |
| (VP HCl 80 mg/tablet) | 0.08 | 0.0809 | 101.125 | 99.29 |
| 0.10 | 0.0996 | 99.60 | 99.82 | |
| Mean ± S.D. | 100.58 ± 0.85 | 99.23 ± 0.62 | ||
| Student’s | 1.734 | (2.776) | ||
| F-test | 1.90 | (19.00) | ||
| Isoptin retard 240 mg tablets | 0.06 | 0.0604 | 100.67 | 99.29 |
| (VP HCl 240 mg/tablet) | 0.08 | 0.0798 | 99.75 | 98.23 |
| 0.10 | 0.0992 | 99.23 | 98.19 | |
| Mean ± S.D. | 99.88 ± 0.73 | 98.57 ± 0.63 | ||
| Student’s | 2.30 | (2.776) | ||
| F-test | 1.38 | (19.00) | ||
| Verapamil 40 mg tablets | 0.06 | 0.0593 | 98.83 | 99.29 |
| (VP HCl 40 mg/tablet) | 0.08 | 0.0795 | 99.38 | 98.94 |
| 0.10 | 0.1007 | 100.70 | 98.55 | |
| Mean ± S.D. | 99.64 ± 0.96 | 98.93 ± 0.37 | ||
| Student’s | 1.20 | (2.776) | ||
| F-test | 6.43 | (19.00) | ||
| Altiazem Retard 60 mg tablets | 0.02 | 0.0199 | 99.50 | 98.72 |
| (DLT HCl 60 mg/tablet) | 0.04 | 0.0406 | 101.50 | 100.25 |
| 0.05 | 0.0507 | 101.40 | 100.62 | |
| Mean ± S.D. | 100.80 ± 1.13 | 99.86 ± 1.01 | ||
| Student’s | 1.070 | (2.776) | ||
| F-test | 1.25 | (19.00) | ||
| Delay-tiazem SR 90 mg capsules | 0.02 | 0.0197 | 98.50 | 97.72 |
| (DLT HCl 90 mg/capsule) | 0.04 | 0.0403 | 100.75 | 101.15 |
| 0.05 | 0.0508 | 101.60 | 98.48 | |
| Mean ± S.D. | 100.28 ± 1.60 | 99.12 ± 1.80 | ||
| Student’s | 0.832 | (2.776) | ||
| F-test | 1.27 | (19.00) | ||
| Delay-tiazem SR 120 mg capsules | 0.02 | 0.0201 | 100.50 | 99.74 |
| (DLT HCl 120 mg/capsule) | 0.04 | 0.0405 | 101.25 | 100.90 |
| 0.05 | 0.0504 | 100.80 | 98.90 | |
| Mean ± S.D. | 100.85 ± 0.38 | 99.85 ± 1.00 | ||
| Student’s | 1.614 | (2.776) | ||
| F-test | 6.94 | (19.00) | ||
| Delay-tiazem SR 180 mg capsules | 0.02 | 0.0204 | 102.00 | 100.94 |
| (DLT HCl 180 mg/capsule) | 0.04 | 0.0404 | 101.00 | 100.00 |
| 0.05 | 0.0505 | 101.00 | 101.13 | |
| Mean ± S.D. | 101.33 ± 0.58 | 100.69 ± 0.61 | ||
| Student’s | 1.312 | (2.776) | ||
| F-test | 1.11 | (19.00) | ||
| Pelcard 50 capsules | 0.06 | 0.0603 | 100.50 | 100.00 |
| (NC HCl 50 mg/capsule) | 0.08 | 0.0810 | 101.25 | 101.39 |
| 0.10 | 0.1013 | 101.30 | 101.45 | |
| Mean ± S.D. | 101.02 ± 0.45 | 100.95 ± 0.82 | ||
| Student’s | 0.130 | (2.776) | ||
| F-test | 3.32 | (19.00) | ||
| Sibelium capsules | 0.06 | 0.0594 | 99.00 | 100.82 |
| (FZ HCl 5 mg/capsule) | 0.08 | 0.0806 | 100.75 | 101.20 |
| 0.10 | 0.1012 | 101.20 | 98.77 | |
| Mean ± S.D. | 100.32 ± 1.16 | 100.26 ± 1.31 | ||
| Student’s | 0.059 | (2.776) | ||
| F-test | 1.27 | (19.00) | ||
Each result is the average of three separate determinations. Figures between parenthesis are the tabulated t and F values, respectively at p=0.05 (50).
Products of the Arab Drug Company, Cairo, Egypt);
Product of El-Nasr Pharmaceutical Chemical Company (Cairo, Egypt);
Product of Lusofarmaco, Cairo, Egypt);
Products of GlaxoWellcome Company, El-Salam City, Cairo, Egypt;
Product of Global Napi & Makram Mehany, Cairo, Egypt);
Product of Janssen Cilag Company, Cairo, Egypt, Under License of Janssen Pharmaceutica-Belgium).
Figure 7Stoichiometry of the reaction between VP and Ce (IV) adopting limiting logarithmic method. A, Log (VP] vs log ΔF; B, Log (Ce (IV)] vs log ΔF.
Figure 8Proposal for the reaction between VP and Ce (IV).
Figure 9Proposal for the reaction between DLT and Ce (IV).
Figure 10Proposal for the reaction between NC and Ce (IV).
Figure 11Proposal for the reaction between FZ and Ce (IV).